Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

News

 

 

Terumo Provides Update on Impact from Hurricane Mariahttps://www.terumo-europe.com/en-emea/news/terumo-provides-update-on-impact-from-hurricane-mariaTerumo Provides Update on Impact from Hurricane MariaTokyo, Japan12/10/2017 22:00:00
Terumo welcomes the positive reimbursement decision for QuiremSpheres® in Belgium as of 1 October 2017https://www.terumo-europe.com/en-emea/news/terumo-welcomes-the-positive-reimbursement-decision-for-quiremspheres®-in-belgium-as-of-1-october-2017Terumo welcomes the positive reimbursement decision for QuiremSpheres® in Belgium as of 1 October 2017Leuven, Belgium20/09/2017 22:00:00<p style="text-align:justify;">Terumo welcomes an important milestone for QuiremSpheres® in Belgium and in Europe. The decision to add QuiremSpheres® to the list of reimbursed radiopharmaceutical products in Belgium was published in the Belgian Official Gazette on 20 September 2017. This will allow hospitals wishing to use QuiremSpheres® to treat patients with advanced unresectable liver cancer to be reimbursed as of 1 October 2017.</p>
Terumo Launches QuiremSpheres® Microspheres in Europehttps://www.terumo-europe.com/en-emea/news/terumo-launches-quiremspheres®-microspheres-in-europeTerumo Launches QuiremSpheres® Microspheres in EuropeTokyo, Japan18/09/2017 22:00:00<p><font size="3">Terumo Corporation (TSE: 4543)announced today thatit has launched QuiremSpheres® microspheres on September 18 in Europe. QuiremSpheres®are available in Europe with plans for expansion in areas outside of Europe in the future.</font></p><font size="3"></font>
Terumo Announces European Medicines Agency Validates Marketing Authorization Application for a Biosimilar to Be Formulatedhttps://www.terumo-europe.com/en-emea/news/terumo-announces-european-medicines-agency-validates-marketing-authorization-application-for-a-biosimilar-to-be-formulatedTerumo Announces European Medicines Agency Validates Marketing Authorization Application for a Biosimilar to Be FormulatedTokyo, Japan22/05/2017 22:00:00<p>​<span>To Accelerate Global Expansion of PLAJEX™</span></p>
First patient enrolled in major new study investigating abbreviated DAPT post-stent in high bleeding risk patientshttps://www.terumo-europe.com/en-emea/news/first-patient-enrolled-in-major-new-study-investigating-abbreviated-dapt-post-stent-in-high-bleeding-risk-patientsFirst patient enrolled in major new study investigating abbreviated DAPT post-stent in high bleeding risk patientsEmmen, The Netherlands03/04/2017 22:00:00<h4>​MASTER-DAPT kicks-off with the enrolment of its first patient by Treant Zorggroep, Scheper Hospital </h4>